Mnemosyne Pharmaceuticals is developing novel therapeutics targeting theĀ NMDA receptor to treatĀ neuropsychiatric disorders. Mnemosyne targets subtypes of the NMDA receptor, the brain's master switch for learning and memory. The company's lead programs are focused on schizophrenia, Rett syndrome, and depression.

Mnemosyne is the Greek goddess of memory and rememberance. The painting in the background above is by Gabriel Dante Rosetti, c. 1875.